Another analysis of 5,487 patients with node-positive BC reported similar 10-year LRRFS and distant recurrence-free survival between HFRT and CFRT groups, and also in high risk subgroups of grade 3, ER−/HER2−, HER2+, and N2–3 (35). Here, ESR1 is linked to breast cancer.